We are committed to serving the best interests of our shareholders.

Filter Releases
 
Press Releases
Date Title and Summary View
9/15/2017 ZUG, Switzerland, Sept. 15, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the Company's marketing authorization application (M...
9/11/2017 MADRID, Spain, Sept. 11, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today provided a summary of ZEJULA and TSR-042, an anti-PD-1 antibody, data presented at the 2017 European Society of Medical Oncology (ESMO) Annual Meeting in Madrid. "ZEJ...
8/25/2017 WALTHAM, Mass., Aug. 25, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that data from nine abstracts will be presented at the 2017 European Society for Medical Oncology (ESMO) annual meeting, September 8 to September 12, 2017, in Madrid. ...
8/23/2017 WALTHAM, Mass., Aug. 23, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation in four upcoming investor conferences. The four conferences are: The Wells Fargo Global Healthcare Conference at ...
8/08/2017 ZEJULA is the most prescribed PARP inhibitor in U.S.; Q2 net sales totaled $26 million in first quarter of availabilityRecently opened European niraparib EAP has enrolled 200 patientsVARUBY oral launch now underway in Europe Dose-escalation o...
7/27/2017 — Takeda's Rights Include all Potential Indications for Niraparib in Japan and Rights Excluding Prostate Cancer in South Korea, Taiwan, Russia and Australia — TESARO to Receive $100...
7/25/2017 WALTHAM, Mass., July 25, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO) will announce its second-quarter 2017 financial results on Tuesday, August 8, 2017, after the close of the U.S. financial markets. TESARO's senior management team will host a conference call and live audio webcast at 4:15 p.m. ET on August 8, 2017 to discuss the Com...
6/29/2017 WALTHAM, Mass., June 29, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, is proud to support the Ovarian Cancer Research Fund Alliance (OCRFA) as the Presenting Sponsor of the 2017 Ovarian Cancer National Conference, being held July 7-9 in Chicago, IL. The OCRFA National Con...
6/28/2017 WALTHAM, Mass., June 28, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, is proud to announce Lonnie Moulder, CEO, and Mary Lynne Hedley, Ph.D., President and COO, have been named EY Entrepreneurs of the Year® in Life Sciences Development for the New England program. The awa...
6/26/2017 WALTHAM, Mass., June 26, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, is proud to support the Healthcare Businesswomen's Association (HBA) as a Corporate Partner. HBA is the leading global organization committed to furthering the advancement and impact of women in healthc...
Page:
...
Next Last
 
= add release to Briefcase